EGFR and non-small cell lung carcinoma: In conclusion, our research has demonstrated that advanced EGFR-mutant NSCLC patients using afatinib as first-line EGFR-TKI treatment experienced significant longer PFS than patients treated with gefitinib, while also showing better results than patients treated with erlotinib.